Washington, DC A protein known to be overly active in breast cancer can exist in a form that seems to change the structural composition of mammary tissue, potentially making it more conducive to tumor progression, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC).
At the annual meeting of the Endocrine Society in Washington, DC, the scientists report that the protein, AIB1 (Amplified in Breast Cancer 1), has a shorter form known as AIB1delta3 which turns breast tissue more fibrous. The researchers say this shorter form may contribute to the dense breast tissue that is a known risk factor for breast cancer.
"We found that AIB1delta3 alters the stroma, or environment that surrounds and supports cancer cells, producing excessive fibrosis," says the study's lead author, Priscilla Furth, MD, Professor of Oncology and Medicine. "This is significant, because disordered interactions between the epithelial and stromal compartments are being increasingly recognized as an important component of breast cancer risk."
A splice variant occurs as the gene is expressed, resulting in deletion of extra amino acids when the protein is formed, changing its shape and possibly its function. Many genes produce these kinds of variants, and the GUMC researchers wanted to know if AIB1delta3 played the same role, or a different one, than its parent larger protein, AIB1, which is known to be over-produced at the RNA level in a significant portion of breast cancers.
Previous research at GUMC has found that AIB1 acts as a co-activator of growth proteins, such as estrogen receptor alpha and HER2/neu, which are also often over-expressed in tumor development. "AIB1 and its more active variant potentiate both estrogen and HER2/Neu at different stages of breast cancer. We knew that AIB1 delta 3 was more active than AIB1 but this study is evidence that we have of a major functional difference between the two protein
|Contact: Karen Mallet|
Georgetown University Medical Center